Indivior Pharmaceuticals (INDV) closed at $34.47 on October 23, 2026, down 2.4% from the previous close, on volume of 1,308,407 shares (30-day average 2,416,760).
Data as of October 23, 2026.
23-Oct-2026
MSG Rangers and Huron Consulting Group to join S&P SmallCap 600
Seeking Alpha News (Fri, 23-Oct 1:19 AM ET)
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
PRNewswire (Thu, 22-Oct 6:09 PM ET)
Indivior to Report Third Quarter 2026 Financial Results
Globe Newswire (Mon, 19-Oct 8:30 AM ET)
Globe Newswire (Wed, 30-Sep 6:42 PM ET)
Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 29-Sep 1:53 PM ET)
ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH
PRNewswire (Mon, 28-Sep 7:22 PM ET)
Business Wire (Thu, 24-Sep 5:16 PM ET)
Indivior Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing
Market Chameleon (Thu, 17-Sep 3:32 AM ET)
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Globe Newswire (Thu, 17-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 10:45 AM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of October 23, 2026, INDV stock price declined to $34.47 with 1,308,407 million shares trading.
INDV has a beta of 0.51, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.03 to the broad based SPY ETF.
INDV has a market cap of $4.07 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $343 million in Revenue and $1.15 earnings per share. This beat revenue expectation by $36 million and exceeded earnings estimates by $.23.
In the last 3 years, INDV traded as high as $42.81 and as low as $7.33.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
INDV has outperformed the market in the last year with a return of +36.4%, while the SPY ETF gained +14.3%. However, in the most recent history, INDV shares have underperformed the stock market with its stock returning -14.9% in the last 3 month period and -3.8% for the last 2 week period, while SPY has returned +3.2% and -2.4%, respectively.
INDV support price is $34.55 and resistance is $36.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.
